|
1
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torres K and Horwitz SB: Mechanisms of
Taxol-induced cell death are concentration dependent. Cancer Res.
58:3620–3626. 1998.PubMed/NCBI
|
|
3
|
Anderson ME: Update on survival in
osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrari S and Serra M: An update on
chemotherapy for osteosarcoma. Expert Opin Pharmacother.
16:2727–2736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jaffe N: Osteosarcoma: Review of the past,
impact on the future. The American experience. Cancer Treat Res.
152:239–262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gai P, Sun H, Wang G, Xu Q, Qi X, Zhang Z
and Jiang L: miR-22 promotes apoptosis of osteosarcoma cells via
inducing cell cycle arrest. Oncol Lett. 13:2354–2358. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Steinhardt AA, Gayyed MF, Klein AP, Dong
J, Maitra A, Pan D, Montgomery EA and Anders RA: Expression of
Yes-associated protein in common solid tumors. Hum Pathol.
39:1582–1589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin J, Dong Q, Zheng M, Xu X, Zou G, Ma G
and Li K: Antitumor activity of dobutamine on human osteosarcoma
cells. Oncol Lett. 11:3676–3680. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kubo M, Morisaki T, Kuroki H, Tasaki A,
Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E and Katano M:
Combination of adoptive immunotherapy with Herceptin for patients
with HER2-expressing breast cancer. Anticancer Res. 23:4443–4449.
2003.PubMed/NCBI
|
|
11
|
Wu C, Jiang J, Shi L and Xu N: Prospective
study of chemotherapy in combination with cytokine-induced killer
cells in patients suffering from advanced non-small cell lung
cancer. Anticancer Res. 28:3997–4002. 2008.PubMed/NCBI
|
|
12
|
Choi D, Kim TG and Sung YC: The past,
present, and future of adoptive T cell therapy. Immune Netw.
12:139–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sangiolo D: Cytokine induced killer cells
as promising immunotherapy for solid tumors. J Cancer. 2:363–368.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Geller MA, Cooley S, Judson PL, Ghebre R,
Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A,
Curtsinger J, McKenna D, et al: A phase II study of allogeneic
natural killer cell therapy to treat patients with recurrent
ovarian and breast cancer. Cytotherapy. 13:98–107. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun C, Sun HY, Xiao WH, Zhang C and Tian
ZG: Natural killer cell dysfunction in hepatocellular carcinoma and
NK cell-based immunotherapy. Acta Pharmacol Sin. 36:1191–1199.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakamoto N, Ishikawa T, Kokura S, Okayama
T, Oka K, Ideno M, Sakai F, Kato A, Tanabe M, Enoki T, et al: Phase
I clinical trial of autologous NK cell therapy using novel
expansion method in patients with advanced digestive cancer. J
Transl Med. 13:2772015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao Y, Hu J, Li R, Song J, Kang Y, Liu S
and Zhang D: Enhanced NK cell adoptive antitumor effects against
breast cancer in vitro via blockade of the transforming growth
factor-β signaling pathway. Onco Targets Ther. 8:1553–1559.
2015.PubMed/NCBI
|
|
18
|
Cheng M, Chen Y, Xiao W, Sun R and Tian Z:
NK cell-based immunotherapy for malignant diseases. Cell Mol
Immunol. 10:230–252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Honorati MC, Neri S, Cattini L and
Facchini A: IL-17 enhances the susceptibility of U-2 OS
osteosarcoma cells to NK cell lysis. Clin Exp Immunol. 133:344–349.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guma SR, Lee DA, Ling Y, Gordon N and
Kleinerman ES: Aerosol interleukin-2 induces natural killer cell
proliferation in the lung and combination therapy improves the
survival of mice with osteosarcoma lung metastasis. Pediatr Blood
Cancer. 61:1362–1368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kiany S, Huang G and Kleinerman ES: Effect
of entinostat on NK cell-mediated cytotoxicity against osteosarcoma
cells and osteosarcoma lung metastasis. Oncoimmunology.
6:e13332142017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Makowska A, Braunschweig T, Denecke B,
Shen L, Baloche V, Busson P and Kontny U: Interferon β and
anti-PD-1/PD-L1 checkpoint blockade cooperate in nk cell-mediated
killing of nasopharyngeal carcinoma cells. Transl Oncol.
12:1237–1256. Jul 8–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carreno BM and Collins M: The B7 family of
ligands and its receptors: New pathways for costimulation and
inhibition of immune responses. Annu Rev Immunol. 20:29–53. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong H and Chen L: B7-H1 pathway and its
role in the evasion of tumor immunity. J Mol Med (Berl).
81:281–287. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pesce S, Greppi M, Grossi F, Del Zotto G,
Moretta L, Sivori S, Genova C and Marcenaro E: PD/1-PD-Ls
checkpoint: Insight on the potential role of NK cells. Front
Immunol. 10:12422019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McDermott DF and Atkins MB: PD-1 as a
potential target in cancer therapy. Cancer Med. 2:662–673.
2013.PubMed/NCBI
|
|
27
|
Swaika A, Hammond WA and Joseph RW:
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Mol Immunol. 67:4–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen BJ, Chapuy B, Ouyang J, Sun HH,
Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA and Rodig
SJ: PD-L1 expression is characteristic of a subset of aggressive
B-cell lymphomas and virus-associated malignancies. Clin Cancer
Res. 19:3462–3473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wimberly H, Brown JR, Schalper K, Haack H,
Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR and Rimm DL:
PD-L1 expression correlates with tumor-infltrating lymphocytes and
response to neoadjuvant chemotherapy in breast cancer. Cancer
Immunol Res. 3:326–332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lussier DM, Johnson JL, Hingorani P and
Blattman JN: Combination immunotherapy with α-CTLA-4 α-PD-L1
antibody blockade and prevent immuneescape and leads to complete
control of metastatic osteosarcoma. J Immunother Cancer. 3:212015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Markel JE, Noore J, Emery EJ, Bobnar HJ,
Kleinerman ES and Lindsey BA: Using the Spleen as an in vivo
systemic immune barometer alongside osteosarcoma disease
progression and Immunotherapy with α-PD-L1. Sarcoma.
2018:86943972018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Koirala P, Roth ME, Gill J, Piperdi S,
Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X and
Gorlick R: Immune infiltration and PD-L1 expression in the tumor
microenvironment are prognostic in osteosarcoma. Sci Rep.
6:300932016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Senju H, Kumagai A, Nakamura Y, Yamaguchi
H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura
H, et al: Effect of IL-18 on the expansion and phenotype of human
natural killer cells: Application to cancer immunotherapy. Int J
Biol Sci. 14:331–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li H, Zhai N, Wang Z, Song H, Yang Y, Cui
A, Li T, Wang G, Niu J, Crispe IN, et al: Regulatory NK cells
mediated between immunosuppressive monocytes and dysfunctional T
cells in chronic HBV infection. Gut. 67:2035–2044. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Choi YH, Lim EJ, Kim SW, Moon YW, Park KS
and An HJ: IL-27 enhances IL-15/IL-18-mediated activation of human
natural killer cells. J Immunother Cancer. 7:1682019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Feng M, Xiong G, Cao Z, Yang G, Zheng S,
Song X, You L, Zheng L, Zhang T and Zhao Y: PD-1/PD-L1 and
immunotherapy for pancreatic cancer. Cancer Lett. 407:57–65. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang ZF, Sun WY, Yu DH, Zhao Y, Xu HM, He
YF and Li HJ: Rotundic acid enhances the impact of radiological
toxicity on MCF-7 cells through the ATM/p53 pathway. Int J Oncol.
53:2269–2277. 2018.PubMed/NCBI
|
|
39
|
Von Pawel J, Bordoni R, Satouchi M,
Fehrenbacher L, Cobo M, Han JY, Hida T, Moro-Sibilot D, Conkling P,
Gandara DR, et al: Long-term survival in patients with advanced
non-small-cell lung cancer treated with atezolizumab versus
docetaxel: Results from the randomised phase III OAK study. Eur J
Cancer. 107:124–132. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Corgnac S, Boutet M, Kfoury M, Naltet C
and Mami-Chouaib F: The emerging role of CD8+ tissue
resident memory T (TRM) cells in antitumor immunity: A
unique functional contribution of the CD103 integrin. Front
Immunol. 9:19042018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
O'Donnell JS, Massi D, Teng MWL and
Mandala M: PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.
Semin Cancer Biol. 48:91–103. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dunai C and Murphy WJ: NK cells for
PD-1/PD-L1 blockade immunotherapy: Pinning down the NK cell. J Clin
Invest. 128:4251–4253. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C,
Peng J, Gao L, Liang X and Ma C: Increased expression of programmed
cell death protein 1 on NK cells inhibits
NK-cell-mediatedanti-tumor function and indicates poor prognosis in
digestive cancers. Oncogene. 36:6143–6153. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brand A, Singer K, Koehl GE, Kolitzus M,
Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, et
al: LDHA-associated lactic acid production blunts tumor
immunosurveillance by T and NK cells. Cell Metab. 24:657–671. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Coca S, Perez-Piqueras J, Martinez D,
Colmenarejo A, Saez MA, Vallejo C, Martos JA and Moreno M: The
prognostic significance of intratumoral natural killer cells in
patients with colorectal carcinoma. Cancer. 79:2320–2328. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Imai K, Matsuyama S, Miyake S, Suga K and
Nakachi K: Natural cytotoxic activity of peripheral-blood
lymphocytes and cancer incidence: An 11-year follow-up study of a
general population. Lancet. 356:1795–1799. 2000. View Article : Google Scholar : PubMed/NCBI
|
